Tumors shrank in 91% of taletrectinib-treated patients with advanced ROS1-positive NSCLC who were ROS1 TKI-naïve and 52% of those who were ROS1 TKI-pretreated in the study
Responses were durable with long-term follow-up; 71% of TKI-naïve patients were still progression-free at two years
TRUST-I is one of two registrational Phase 2 studies evaluating taletrectinib for the treatment of patients with advanced ROS1-positive NSCLC
NEW YORK--(BUSINESS... (continue reading...)
Publication Entitled: Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial
HARMONi-A was Featured in Oral Presentation at ASCO 2024 on May 31, 2024
Conference Call to be Held at 8:00am ET on Monday, June 3, 2024
MIAMI--(BUSINESS WIRE)-- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) announced that the Journal of the American Medical Association (JAMA) published a... (continue reading...)
– Data Support the Ongoing Phase 3 STAR-221 Study of Domvanalimab Plus Zimberelimab and Chemotherapy, Potentially the First Anti-TIGIT Combination to Market for These Cancers –
– Results will be Presented Today During an Oral Session at the ASCO Annual Meeting –
FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced longer-term efficacy and safety results... (continue reading...)
− Four-year Analysis Conducted by GHSG Reported ADCETRIS + ECADD Combination Improved Progression-Free Survival, Showing Superior Efficacy and Tolerable Safety Profile in Patients with Newly Diagnosed Stage IIb/III/IV Classical Hodgkin Lymphoma vs eBEACOPP, a Current Standard of Care in This Setting in Europe
− The HD21 Study Adds to the Body of Evidence Supporting ADCETRIS as a Backbone Agent in the Treatment of Specific Lymphomas
− Results To Be Featured as... (continue reading...)
- Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone, resulting in median overall survival of 13.8 months versus 8.5 months
- Third Phase 3 trial in third type of lymphoma to show improvement in overall survival with an ADCETRIS-containing regimen
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced detailed overall survival (OS) results from... (continue reading...)
More Business Wire
View Older Stories-
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Canc
-
Massive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024
-
Accutar Biotechnology Presents Phase 1 Data of AC699 Monotherapy in Patients with ER+ / HER2- Breast Cancer at ASCO 2024
-
Clariane: Information on the Availability of an Amendment to the 2023 Universal Registration Document
-
AnalytixInsight Reports 2023 Financial Results and Provides MCTO Status Update
-
The Chemours Company Temporarily Pauses Titanium Dioxide Production at Altamira, Mexico Site Amid Severe Regional Drought
-
Generation Mining Files Final Base Shelf Prospectus and Updates Shareholders
-
Tikehau Capital: Disclosure of shares repurchases from 24 May 2024 to 30 May 2024
-
Government Regulation Creates Blue Oceans
-
Inocras Presents Poster for Breast Cancer at 2024 ASCO Annual Meeting, Showing Transformative Impact of WGS-based HRD Testing
-
Leading Independent Proxy Advisory Firm Institutional Shareholder Services Joins Glass Lewis in Recommending Votes “FOR” ALL Nine WisdomTree Board Nominees
-
BRW Announces Notification of Sources of Distributions
-
SABA Announces Notification of Sources of Distributions
-
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Che
-
FCPT Announces Acquisition of a Mavis Tire Property for $2.4 Million
-
University of Phoenix and Executive Networks Study on Workplace Well-Being Highlights Challenges of Current Approaches in Addressing Mental Health
-
Capstone Copper Announces Retirement of Robert Gallagher from the Board of Directors
-
Drive Shack Inc. Releases Fourth Quarter and Full-Year 2023 Financial Results
-
Medical Properties Trust Publishes Its Third Annual Corporate Responsibility Report
-
FCPT Announces Acquisition of a National Veterinary Associates Property for $2.0 Million
-
Fonon's Additive Manufacturing Technology To Transform Construction Industry
-
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
Ventas to Present at Nareit’s REITweek 2024 Investor Conference
-
Korn Ferry Recognized for Seventh Consecutive Year as a Leader in Everest Group’s Recruitment Process Outsourcing (RPO) Services PEAK Matrix® Assessment 2024
-
Boston Omaha Corporation Announces Date for 2024 Annual Meeting of Stockholders
-
Darwin’s Natural Pet Products Continues Ongoing Partnership with PAWS for Annual PAWS Walk
-
Ault Disruptive Technologies Responds to Unusual Market Activity
-
Hope Biosciences Research Foundation Announces Topline Results of Cell Therapy Clinical Trial in Long COVID
-
State Street Corporation (NYSE: STT) Announces Date for Release of Second-Quarter 2024 Financial Results and Conference Call Webcast
-
MedX Health Corp. announces proposed extension of Non-brokered Private Placement offering
-
SITE Centers Declares Second Quarter 2024 Class A Preferred Share Dividend
-
Equity Residential to Participate in Nareit REITweek Conference
-
UBS Announces Assumption of Three Outstanding Credit Suisse ETNs; Rebranding as “ETRACS”
-
Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions
-
PulteGroup, Inc. Announces Pricing for Tender Offers for Senior Notes
-
Westlake Chemical Partners Provides Tax Reporting Information
-
Camden Property Trust Announces Participation in Nareit’s REITweek 2024 Investor Conference and Provides Second Quarter 2024 Operating Update
-
Pacific Coast Oil Trust Announces There Will Be No May Cash Distribution
-
AvalonBay Communities, Inc. Announces Participation in Nareit’s REITweek Conference, Provides Second Quarter 2024 Operating Update, and Publishes Updated Investor Presentation
-
PGIM Closed End Funds Declare Distributions for June, July and August 2024
-
Emerald to Participate in Maxim Group TMT Conference
-
Bradley E. Cooper Appointed to Hamilton Board of Directors
-
Eaton Expands Reach into European Data Center Market by Making Strategic Investment in NordicEPOD
-
First Trust Advisors L.P. Announces Distribution for Exchange-Traded Funds
-
Asana to Present at Upcoming Investor Events
-
FCPT Announces Acquisition of a BluePearl Pet Hospital Property for $1.9 Million
-
Bruker Corporation to Present at Upcoming Investor Conferences
-
InvenTrust Properties Corp. Announces Second Quarter 2024 Cash Dividend
-
Eaton Vance Closed-End Funds Release Estimated Sources of Distributions